{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:09:03Z","timestamp":1791216543065,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Scientific Research Fund of Zhejiang Provincial Education Department","award":["Y201224146"],"award-info":[{"award-number":["Y201224146"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12944-015-0114-2","type":"journal-article","created":{"date-parts":[[2015,10,5]],"date-time":"2015-10-05T19:28:15Z","timestamp":1444073295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis"],"prefix":"10.1186","volume":"14","author":[{"given":"Jia","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,6]]},"reference":[{"key":"114_CR1","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","volume":"364","author":"S Yusuf","year":"2004","unstructured":"Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case\u2013control study. Lancet. 2004;364:937\u201352.","journal-title":"Lancet"},{"key":"114_CR2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"PS Sever","year":"2003","unstructured":"Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial\u2013Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149\u201358.","journal-title":"Lancet"},{"key":"114_CR3","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","volume":"28","author":"PS Sever","year":"2005","unstructured":"Sever PS, Poulter NR, Dahlof B, Wedel H, Collins R, Beevers G, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151\u20137.","journal-title":"Diabetes Care"},{"key":"114_CR4","first-page":"34F","volume":"96","author":"AM Gotto Jr","year":"2005","unstructured":"Gotto Jr AM. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. Am J Cardiol. 2005;96:34F\u20138F.","journal-title":"Am J Cardiol"},{"key":"114_CR5","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.atherosclerosis.2005.05.025","volume":"185","author":"D Bercovich","year":"2006","unstructured":"Bercovich D, Friedlander Y, Korem S, Houminer A, Hoffman A, Kleinberg L, et al. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis. 2006;185:97\u2013107.","journal-title":"Atherosclerosis"},{"key":"114_CR6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0005-2736(99)00161-3","volume":"1461","author":"I Klein","year":"1999","unstructured":"Klein I, Sarkadi B, Varadi A. An inventory of the human ABC proteins. Biochim Biophys Acta. 1999;1461:237\u201362.","journal-title":"Biochim Biophys Acta"},{"key":"114_CR7","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/BF01570737","volume":"12","author":"A Fojo","year":"1986","unstructured":"Fojo A, Lebo R, Shimizu N, Chin JE, Roninson IB, Merlino GT, et al. Localization of multidrug resistance-associated DNA sequences to human chromosome 7. Somat Cell Mol Genet. 1986;12:415\u201320.","journal-title":"Somat Cell Mol Genet"},{"key":"114_CR8","first-page":"45","volume":"16","author":"JP Kitzmiller","year":"2013","unstructured":"Kitzmiller JP, Binkley PF, Pandey SR, Suhy AM, Baldassarre D, Hartmann K. Statin pharmacogenomics: pursuing biomarkers for predicting clinical outcomes. Discov Med. 2013;16:45\u201351.","journal-title":"Discov Med"},{"key":"114_CR9","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.amjcard.2004.01.014","volume":"93","author":"K Kajinami","year":"2004","unstructured":"Kajinami K, Brousseau ME, Ordovas JM, Schaefer EJ. Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner. Am J Cardiol. 2004;93:1046\u201350.","journal-title":"Am J Cardiol"},{"key":"114_CR10","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.clpt.2005.08.003","volume":"78","author":"M Fiegenbaum","year":"2005","unstructured":"Fiegenbaum M, da Silveira FR, Van der Sand CR, Van der Sand LC, Ferreira ME, Pires RC, et al. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther. 2005;78:551\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"114_CR11","doi-asserted-by":"crossref","first-page":"144","DOI":"10.17305\/bjbms.2014.3.43","volume":"14","author":"A Salacka","year":"2014","unstructured":"Salacka A, Binczak-Kuleta A, Kaczmarczyk M, Hornowska I, Safranow K, Clark JS. Possible association of ABCB1:c.3435T>C polymorphism with high-density-lipoprotein-cholesterol response to statin treatment--a pilot study. Bosn J Basic Med Sci. 2014;14:144\u20139.","journal-title":"Bosn J Basic Med Sci"},{"key":"114_CR12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.cca.2011.11.003","volume":"413","author":"A Rosales","year":"2012","unstructured":"Rosales A, Alvear M, Cuevas A, Saavedra N, Zambrano T, Salazar LA. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia. Clin Chim Acta. 2012;413:495\u2013501.","journal-title":"Clin Chim Acta"},{"key":"114_CR13","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1590\/S0100-879X2005000900014","volume":"38","author":"AC Rodrigues","year":"2005","unstructured":"Rodrigues AC, Rebecchi IM, Bertolami MC, Faludi AA, Hirata MH, Hirata RD. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent. Braz J Med Biol Res. 2005;38:1389\u201397.","journal-title":"Braz J Med Biol Res"},{"key":"114_CR14","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40291-013-0038-3","volume":"17","author":"MF Shabana","year":"2013","unstructured":"Shabana MF, Mishriki AA, Issac MS, Bakhoum SW. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia. Mol Diagn Ther. 2013;17:299\u2013309.","journal-title":"Mol Diagn Ther"},{"key":"114_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jacl.2011.01.001","volume":"5","author":"MR Hoenig","year":"2011","unstructured":"Hoenig MR, Walker PJ, Gurnsey C, Beadle K, Johnson L. The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. J Clin Lipidol. 2011;5:91\u20136.","journal-title":"J Clin Lipidol"},{"key":"114_CR16","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00228-014-1661-6","volume":"70","author":"M Ferrari","year":"2014","unstructured":"Ferrari M, Guasti L, Maresca A, Mirabile M, Contini S, Grandi AM, et al. Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2. Eur J Clin Pharmacol. 2014;70:539\u201347.","journal-title":"Eur J Clin Pharmacol"},{"key":"114_CR17","doi-asserted-by":"crossref","first-page":"858","DOI":"10.7326\/0003-4819-150-12-200906160-00009","volume":"150","author":"TR Joy","year":"2009","unstructured":"Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858\u201368.","journal-title":"Ann Intern Med"},{"key":"114_CR18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1469-1809.1955.tb01348.x","volume":"19","author":"B Woolf","year":"1955","unstructured":"Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251\u20133.","journal-title":"Ann Hum Genet"},{"key":"114_CR19","doi-asserted-by":"crossref","first-page":"820","DOI":"10.7326\/0003-4819-127-9-199711010-00008","volume":"127","author":"J Lau","year":"1997","unstructured":"Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820\u20136.","journal-title":"Ann Intern Med"},{"key":"114_CR20","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557\u201360.","journal-title":"BMJ"},{"key":"114_CR21","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1136\/bmj.320.7249.1574","volume":"320","author":"AJ Sutton","year":"2000","unstructured":"Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ. 2000;320:1574\u20137.","journal-title":"BMJ"},{"key":"114_CR22","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1210\/jcem.87.2.8057","volume":"87","author":"RA Kreisberg","year":"2002","unstructured":"Kreisberg RA, Oberman A. Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies. J Clin Endocrinol Metab. 2002;87:423\u201337.","journal-title":"J Clin Endocrinol Metab"},{"key":"114_CR23","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/00007691-200002000-00029","volume":"22","author":"Y Tanigawara","year":"2000","unstructured":"Tanigawara Y. Role of P-glycoprotein in drug disposition. Ther Drug Monit. 2000;22:137\u201340.","journal-title":"Ther Drug Monit"},{"key":"114_CR24","doi-asserted-by":"crossref","first-page":"e46366","DOI":"10.1371\/journal.pone.0046366","volume":"7","author":"J Su","year":"2012","unstructured":"Su J, Xu J, Li X, Zhang H, Hu J, Fang R, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One. 2012;7:e46366.","journal-title":"PLoS One"},{"key":"114_CR25","doi-asserted-by":"crossref","first-page":"10347","DOI":"10.1073\/pnas.162366399","volume":"99","author":"A Garrigues","year":"2002","unstructured":"Garrigues A, Escargueil AE, Orlowski S. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane. Proc Natl Acad Sci U S A. 2002;99:10347\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"114_CR26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.bbalip.2005.01.003","volume":"1733","author":"M Tous","year":"2005","unstructured":"Tous M, Ribas V, Ferre N, Escola-Gil JC, Blanco-Vaca F, Alonso-Villaverde C, et al. Turpentine-induced inflammation reduces the hepatic expression of the multiple drug resistance gene, the plasma cholesterol concentration and the development of atherosclerosis in apolipoprotein E deficient mice. Biochim Biophys Acta. 2005;1733:192\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"114_CR27","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.cca.2009.02.019","volume":"403","author":"E Jeannesson","year":"2009","unstructured":"Jeannesson E, Siest G, Bastien B, Albertini L, Aslanidis C, Schmitz G, et al. Association of ABCB1 gene polymorphisms with plasma lipid and apolipoprotein concentrations in the STANISLAS cohort. Clin Chim Acta. 2009;403:198\u2013202.","journal-title":"Clin Chim Acta"},{"key":"114_CR28","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcp.2008.09.019","volume":"77","author":"IM Rebecchi","year":"2009","unstructured":"Rebecchi IM, Rodrigues AC, Arazi SS, Genvigir FD, Willrich MA, Hirata MH, et al. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol. 2009;77:66\u201375.","journal-title":"Biochem Pharmacol"},{"key":"114_CR29","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jacl.2014.07.010","volume":"8","author":"Q Li","year":"2014","unstructured":"Li Q, Hong J, Wu J, Huang ZX, Li QJ, Yin RX, et al. The role of common variants of ABCB1 and CYP7A1 genes in serum lipid levels and lipid-lowering efficacy of statin treatment: a meta-analysis. J Clin Lipidol. 2014;8:618\u201329.","journal-title":"J Clin Lipidol"},{"key":"114_CR30","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.atherosclerosis.2015.02.003","volume":"239","author":"MU Aydin","year":"2015","unstructured":"Aydin MU, Aygul N, Altunkeser BB, Unlu A, Taner A. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction. Atherosclerosis. 2015;239:439\u201343.","journal-title":"Atherosclerosis"},{"key":"114_CR31","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2217\/pgs.12.11","volume":"13","author":"Q Feng","year":"2012","unstructured":"Feng Q, Wilke RA, Baye TM. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions. Pharmacogenomics. 2012;13:579\u201394.","journal-title":"Pharmacogenomics"},{"key":"114_CR32","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","volume":"289","author":"PD Thompson","year":"2003","unstructured":"Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681\u201390.","journal-title":"JAMA"},{"key":"114_CR33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.amjmed.2003.10.033","volume":"116","author":"RS Rosenson","year":"2004","unstructured":"Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116:408\u201316.","journal-title":"Am J Med"},{"key":"114_CR34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejim.2015.01.002","volume":"26","author":"P Magni","year":"2015","unstructured":"Magni P, Macchi C, Morlotti B, Sirtori CR, Ruscica M. Risk identification and possible countermeasures for muscle adverse effects during statin therapy. Eur J Intern Med. 2015;26:82\u20138.","journal-title":"Eur J Intern Med"},{"key":"114_CR35","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S1474-4422(09)70058-4","volume":"8","author":"P Amarenco","year":"2009","unstructured":"Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol. 2009;8:453\u201363.","journal-title":"Lancet Neurol"},{"key":"114_CR36","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.amjcard.2005.09.134","volume":"97","author":"JA Simon","year":"2006","unstructured":"Simon JA, Lin F, Hulley SB, Blanche PJ, Waters D, Shiboski S, et al. Phenotypic predictors of response to simvastatin therapy among African-Americans and Caucasians: the Cholesterol and Pharmacogenetics (CAP) study. Am J Cardiol. 2006;97:843\u201350.","journal-title":"Am J Cardiol"},{"key":"114_CR37","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/QAD.0b013e32801120e3","volume":"20","author":"F Boccara","year":"2006","unstructured":"Boccara F, Simon T, Lacombe K, Cohen A, Laloux B, Bozec E, et al. Influence of pravastatin on carotid artery structure and function in dyslipidemic HIV-infected patients receiving antiretroviral therapy. AIDS. 2006;20:2395\u20138.","journal-title":"AIDS"},{"key":"114_CR38","doi-asserted-by":"crossref","unstructured":"Al-Sarraf A, Li M, Frohlich J. Statin resistant dyslipidemia in a patient treated with amiodarone. BMJ Case Rep. 2011;2011. doi:10.1136\/bcr.08.2011.4620.","DOI":"10.1136\/bcr.08.2011.4620"},{"key":"114_CR39","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/ATVBAHA.113.301301","volume":"34","author":"Y Chen","year":"2014","unstructured":"Chen Y, Ku H, Zhao L, Wheeler DC, Li LC, Li Q, et al. Inflammatory stress induces statin resistance by disrupting 3-hydroxy-3-methylglutaryl-CoA reductase feedback regulation. Arterioscler Thromb Vasc Biol. 2014;34:365\u201376.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"114_CR40","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","volume":"24","author":"Z Reiner","year":"2014","unstructured":"Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24:1057\u201366.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"114_CR41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1472-8206.2009.00764.x","volume":"24","author":"Z Reiner","year":"2010","unstructured":"Reiner Z. Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol. 2010;24:19\u201328.","journal-title":"Fundam Clin Pharmacol"},{"key":"114_CR42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ahj.2014.05.004","volume":"168","author":"MA Blazing","year":"2014","unstructured":"Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J. 2014;168:205\u201312. e201.","journal-title":"Am Heart J"},{"key":"114_CR43","doi-asserted-by":"crossref","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015.","DOI":"10.1056\/NEJMoa1501031"},{"key":"114_CR44","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015.","DOI":"10.1056\/NEJMoa1500858"},{"key":"114_CR45","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrcardio.2014.84","volume":"11","author":"RT Dadu","year":"2014","unstructured":"Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol. 2014;11:563\u201375.","journal-title":"Nat Rev Cardiol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-015-0114-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T16:49:15Z","timestamp":1498236555000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.lipidworld.com\/content\/14\/1\/122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,6]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["114"],"URL":"https:\/\/doi.org\/10.1186\/s12944-015-0114-2","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,6]]},"article-number":"122"}}